## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#8 NOB 10-4-01

In regard to the application of: Ari DEROWE et al.

Serial No:

09/701,531

Group Art Unit: 3736

Filed

November 28, 2000

Examiner: Unknown

For

METHODS AND DEVICES FOR VASCULAR SURGERY

## THIRD SUPPLEMENTARY INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner of Patents and Trademarks Washington, DC 20231

Sir:

Applicants respectfully direct the attention of the Examiner to additional art execution with respect to U.S. Application No. 09/701,531.

The Examiner is respectfully requested to review and consider this art, in accordance with MPEP 2001.06, MPEP 1893.03(e) and MPEP 1893.03(g) and to indicate in the first office action that he has considered this art. Additionally, the Examiner is respectfully requested to cite those prior art publications mentioned in this application which the Examiner considers to be material or relevant to the present claims.

Further, in order to comply with discretionary regulations 37 CFR 1.97 and 1.98, attached is Form PTO-1449 listing the cited art. Also attached are copies of the art. This art contains information which the Examiner may consider to be important in deciding whether to allow the present application to issue as a patent.

Applicants wish to bring to the attention of the Examiner that items 1 and 2 were filed between the earliest priority date (May 29, 1998) and the international filing date of the present application (May 30, 1999). It is not clear to the applicants whether these publications should be considered by the Examiner. However, for the sake of completeness, they have been cited on the PTO-1449 form and copies of them have been attached hereto.

In accordance with MPEP Section 609 it is requested that each document cited [including any mentioned in Applicants' specification which is not repeated on the attached (or

<sup>&</sup>lt;sup>1</sup> To the extent that a document is listed and no copy of same is attached, then such document is not at the present time available to the undersigned or is available in the national stage file. If a listed document is not in the English language and an English translation is readily available, such translation is also attached; if translation is not attached, it is not readily available to the undersigned. If a foreign language patent document is cited, and an English language equivalent is known to the undersigned, then such an equivalent patent is also cited on the attached form along with the corresponding foreign language patent and a connecting arrow indicated therebetween; if no such English language equivalent is cited then none is known to the undersigned.

prior) PTO-1449 form(s)] be given thorough consideration and be cited of record in the prosecution history of the present application by initialing on the PTO-1449 form, so that it will appear on the face of the patent issuing on the present application, even if the Examiner does not consider it sufficiently pertinent to use in a rejection, or otherwise does not believe that the guidelines for citation have been fully complied with.

The present Information Disclosure Statement is being submitted in compliance with 37 CFR 1.56 as an Examiner might consider any cited document important in deciding whether to allow the application to issue as a patent, but the citation of each document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a), and in the course of such search will review for relevance every document cited on the attached form.

Early and favorable consideration is earnestly solicited.

Respectfully submitted, Ari DEROWE et al.

Maier FENSTER

Registration No. 41,016

September 9, 2001 William H. Dippert, Esq. Cowan, Liebowitz & Latman, P.C. 1133 Avenue of the Americas New York, NY 10036-6799

Tel: (212) 790-9200

P10A/REV01

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))				Docket No. 088/01925	
In Re	Application Of:	Ari DEROWE et al.			
Serial No. 09/701,531		Filing Date November 28, 2000	Examiner Unknown	Group Art Unit 3736	
SEP 2 0	· K	D DEVICES FOR VASCULAR	SURGERY		
& TRADE	AARK!	Assistant Com	dress to: nissioner for Patents on, D.C. 20231		
		37 CI	FR 1.97(b)		
1. 🖾	1.  The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application; within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or before the mailing date of a first Office Action on the merits, whichever event occurs last.				
		37 CI	FR 1.97(c)		
2. 🗆	The Information Disclosure Statement submitted herewith is being filed after three months of the filing of a national application, or the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or after the mailing date of a first Office Action on the merits, whichever occurred last but before the mailing date of either:				
	1.	a Final Action under 37 CFR 1.1	13, or		
	2.	a Notice of Allowance under 37 (	CFR 1.311,		
	whichever occurs first.				
	Also submitted herewith is:				
	☐ a certification as specified in 37 CFR 1.97(e);				
		OR			
	the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under 37 CFR 1.97(c).				
				RECEIVEI SEP 2,4 2001 TECHNOLOGY CENTER RO	

Copyright 1996 Legalsoft

Attorney Signature Signature

September 17, 2001 Date of Signature

The Commissioner is hereby authorized to charge any additional fee which may be required, or credit any overpayment to Account No. 03-3415.